Small molecule · Inhibitor of mitogen-activated protein kinase 14 (p38α) (MAPK14) · developed by EIP Pharma
Phase 2Most advanced trial
1Registered trials
What is Neflamapimod?
Neflamapimod is a highly specific inhibitor of the intracellular enzyme mitogen-activated protein kinase 14 (p38α). It is being studied in nonfluent variant primary progressive aphasia.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
VX-745, VD-31745, VRT-031745
Drug type
Small molecule
Targets
mitogen-activated protein kinase 14 (p38α) (MAPK14)
Mechanism
Inhibitor of mitogen-activated protein kinase 14 (p38α) (MAPK14)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.